The Bureau International des Expositions (BIE) announces the official list of candidates for Specialised Expo 2022/23: Poland (Łódź), United States (Minneapolis), Brazil (Rio de Janeiro) and Argentina (Buenos Aires)
The Bureau International des Expositions (BIE) has closed the candidature period for Specialised Expo 2022/23. Four countries have submitted competing bids to organise Specialised Expo 2022/23: the Republic of Poland, the United States of America, the Federative Republic of Brazil and the Republic of Argentina.
The 169 Member States of the BIE will elect the host country of Specialised Expo 2022/23 at the 162nd General Assembly in November 2017.
Poland’s bid is for a Specialised Expo in the city of Łódź between 15 June and 15 September 2022 under the theme “City Re:Invented.”
The United States’ bid is for a Specialised Expo in Minneapolis between 15 May and 15 August 2023 under the theme “Wellness and Well Being for All: Healthy People, Healthy Planet.” The United States is not a Member State of the BIE.*
Brazil’s bid is for a Specialised Expo in Rio de Janeiro between 4 March and 27 May 2022 under the theme “Metropolitan Cities and Sustainability: Cross Border Potentials.”
Argentina’s bid is for a Specialised Expo in Buenos Aires between 15 January and 15 April 2023 under the theme “Science, Innovation, Art and Creativity for the Human Development.”
The Secretary General of the BIE, Vicente G. Loscertales, stated that “these four candidatures demonstrate a high level of interest for this type of Expo.” The project examination phase for Specialised Expo 2022/23 will take place over the next few months. Each candidate will submit a bid dossier, to be followed by a BIE Enquiry Mission. The projects will then be presented to the General Assembly of the BIE on 14 June 2017. The election of the host country by the 169 Member States of the BIE will take place at the subsequent General Assembly in November 2017.
Specialised Expos, known officially as International Recognised Exhibitions, can be organised in the interval between two World Expos. They can last up to three months and are designed to respond to a precise challenge facing humanity. The most recent Specialised Expo was held in the city of Yeosu in the Republic of Korea in 2012, which attracted over 8 million visitors under the theme “The Living Ocean and Coast”. The next Specialised Expo is to take place in Astana, the capital of Kazakhstan, between 10 June and 10 September 2017 under the theme “Future Energy”.
* In accordance with BIE regulations, Member States must be given priority over non-Member States.
The Bureau International des Expositions (BIE) is the intergovernmental organisation embodying the commitment of its 169 member States to lead, promote and foster International Exhibitions for the benefit of the citizens of the international community.
The BIE oversees four types of International Exhibitions: World Expos (International Registered Exhibitions), Specialised Expos (International Recognised Exhibitions), Horticultural Expos and the Triennale di Milano.
International Exhibitions are global events dedicated to finding solutions to specific challenges facing humanity by offering a journey inside the Expo theme through engaging and immersive activities.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i